

# 8th Urologic Oncology:

Advances in Clinical Practice

November 8–9, 2013

MD Anderson  
Dan L. Duncan Building  
Conference Center, Floor 8  
1155 Pressler  
Houston, Texas

THE UNIVERSITY OF TEXAS  
**MDAnderson**  
**Cancer Center**

Making Cancer History®

# 8th Urologic Oncology: Advances in Clinical Practice

November 8-9, 2013

## Focus

The 8th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced bladder, prostate, kidney, penile and testis cancers.

## Educational Objectives

After attending the conference, participants should be able to

- Implement and illustrate clinical advances in the diagnosis and evaluation of bladder, prostate, kidney, penile and testis cancers (*Knowledge, Competence, Performance, Patient Outcomes*);
- Implement and illustrate clinical advances in the treatment approach to localized and locally advanced bladder, prostate, kidney, penile and testis cancers (*Knowledge, Competence, Performance, Patient Outcomes*);
- Implement and illustrate clinical advances in the treatment approach to metastatic bladder, prostate, kidney, penile and testis cancers (*Knowledge, Competence, Performance, Patient Outcomes*);
- Identify and access contemporary controversies in the management of bladder, prostate, kidney, penile and testis cancers (*Knowledge, Competence*).

## Educational Methods

Lectures – Case Presentations – Panel Discussions – Audience Response System – Question and Discussion Sessions

## Target Audience

This conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants.

## Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

## Accreditation/Credit Designation

### Physicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA PRA Category 1 Credit*™ or certificates documenting attendance will be distributed to participants as they depart the symposium. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

## MD Anderson Organizing Committee

### Conference Chairmen

#### **Christopher G. Wood, MD**

Program Co-Chairman  
Professor and Vice Chairman  
Urology

#### **Nizar M. Tannir, MD**

Program Co-Chairman  
Associate Professor and Vice Chairman  
Genitourinary Medical Oncology

### Conference Committee

#### **Ana Aparicio, MD**

Assistant Professor  
Genitourinary Medical Oncology

#### **Brian F. Chapin, MD**

Assistant Professor  
Urology

#### **John W. Davis, MD**

Associate Professor  
Urology

#### **Colin P. Dinney, MD**

Professor and Chairman  
Urology

#### **Jay B. Shah, MD**

Assistant Professor  
Urology

#### **Arlene Siefker-Radtke, MD**

Associate Professor  
Genitourinary Medical Oncology

#### **Gloria Curtis**

Sr. Administrative Assistant  
Genitourinary Medical Oncology

#### **Carol Fournitia**

Sr. Administrative Assistant  
Urology

#### **Constance C. Tierney, CMP**

Manager  
CME/Conference Management

# Program

## Urologic Oncology: Advances in Clinical Practice

Friday, November 8, 2013

7:00 a.m. Registration and Continental Breakfast

7:50 **Welcome and Opening Remarks**

Christopher G. Wood, MD and Nizar M. Tannir, MD

### SESSION I: PENILE/TESTIS CANCER

*Moderator: Louis L. Pisters, MD*

8:00 **Update on Surgical Options for Localized and Locally Advanced Penile Cancer**

Curtis A. Pettaway, MD

8:20 **Update on Chemotherapy Options for Locally Advanced and Metastatic Penile Cancer**

Lance C. Pagliaro, MD

8:40 **Distinguished Alumnus Presentation  
Topical Therapy for Non-Muscle Invasive Urothelial Carcinoma:  
Past, Present & Future**

Wade J. Sexton, MD

9:00 **Management of High Risk Stage I Testis Cancer**

### Case Presentation

22 year old WM presents with right testicular mass. Metastatic evaluation negative. AFP 90 ng/ml,  $\beta$ -HCG<1.0 mIU/ml. Undergoes right radical orchiectomy. Pathology 70% embryonal, 25% teratoma, 5% seminoma. Invasion into the rete testis. +LVI. Markers normalize appropriately after surgery.

#### **Observation**

Jose A. Karam, MD

#### **Chemotherapy**

Jennifer Wang, MD

#### **RPLND**

John F. Ward, MD

9:45 **Risk Adapted Management of Patients With  
Advanced Poor-Risk NSGCT**

Lance C. Pagliaro, MD

- 10:00      **Management of Patients With Platinum Refractory Advanced Germ Cell Tumors: Role of High-Dose Chemotherapy and Stem Cell Transplantation**  
Yago Nieto, MD
- 10:15      **Questions and Discussion**
- 10:25      Break
- 10:40      **Outcomes and Complications of Post-Chemotherapy RPLND for Metastatic Testis Cancer**  
Louis L. Pisters, MD
- 10:55      **Management of the Residual Mass in Metastatic Seminoma s/p Chemotherapy**  
Shi-Ming Tu, MD
- 11:10      **Case Presentations**  
*Moderators: Curtis A. Pettaway, MD and Louis L. Pisters, MD*  
Panelists: Jose A. Karam, MD; Yago Nieto, MD; Lance L. Pagliaro, MD; Wade J. Sexton, MD; Shi-Ming Tu, MD; John F. Ward, MD
- Noon      Lunch (Provided)

## SESSION II: UROTHELIAL CANCER

### Superficial Bladder Cancer

*Moderator: Jay B. Shah, MD*

- 1:00 p.m.      **Novel Approaches to Localized Bladder Cancer**  
Colin P. Dinney, MD
- 1:10      **Controversy: Recurrent T1HG After Induction BCG**  
  
                  **Continued Intravesical Therapy is Best**  
                  Colin P. Dinney, MD  
  
                  **Immediate Cystectomy is Best**  
                  Ashish Kamat, MD  
  
                  **Chemoradiation is Best**  
                  Karen Hoffman, MD

### Upper Tract Disease

*Moderator: Jay B. Shah, MD*

- 1:40      **Treatment of Superficial Upper Tract Transitional Cell Carcinoma**  
Surena F. Matin, MD

- 1:50      **Controversy: HG Tumor of Left Distal Ureter**  
            **Immediate Distal Ureterectomy is Best**  
            Neema Navai, MD  
  
            **Neoadjuvant Chemotherapy is Best**  
            Arlene Siefker-Radtke, MD
- 2:00      **Questions and Discussion**  
  
            **Case Presentations**  
            *Moderator: Jay B. Shah, MD*  
            Panelists: Colin P. Dinney, MD; Karen Hoffman, MD; Ashish Kamat, MD;  
            Surena F. Matin, MD; Neema Navai, MD; Wade J. Sexton, MD;  
            Arlene Siefker-Radtke, MD
- 2:40      Break

## **Invasive Urothelial Cancer**

*Moderator: Arlene Siefker-Radtke, MD*

- 3:00      **Controversy: 63 Year Old Man With T2 Bladder Cancer**  
            **Open Cystectomy is the Best Option**  
            Ashish Kamat, MD  
  
            **Robotic Cystectomy is the Best Option**  
            Jay B. Shah, MD
- 3:20      **Controversy: 63 Year Old Man Undergoing Cystectomy Needs Urinary Diversion**  
            **Orthotopic Neobladder is Best Choice**  
            H. Barton Grossman, MD  
  
            **Continent Cutaneous Diversion is Best Choice**  
            O. Lenaine Westney, MD  
  
            **Ileal Conduit is Best Choice**  
            Jay B. Shah, MD
- 3:50      **Controversy: 63 Year Old Man With T3 Bladder Cancer Wants Neoadjuvant Chemo**  
            **MCAC is Best Choice**  
            Jianjun Gao, MD, PhD  
  
            **Gem/Cis is Best**  
            Arlene Siefker-Radtke, MD
- 4:10      **Novel Chemo Situations and Novel Chemo Options**  
            Arlene Siefker-Radtke, MD

4:20      **Questions and Discussion**

**Case Presentations**

*Moderator: Arlene Siefker-Radtke, MD*

Panelists: Jianjun Gao, MD, PhD; H. Barton Grossman, MD;  
Ashish Kamat, MD; Jay B. Shah, MD; O. Lenaine Westney, MD

5:00      Break

5:15      **Andrew C. von Eschenbach Lecture**  
**Maximizing Perioperative Management of the IVC for Tumor**  
**Thrombectomy Improves Safety of Radical Nephrectomy**  
Michael Blute, Sr., MD

6:00      Reception

## Saturday, November 9, 2013

7:00 a.m.      Registration and Continental Breakfast

### SESSION III: RENAL CANCER

*Moderator: Christopher G. Wood, MD*

8:00      **Management of Small Renal Mass Debate**

#### Case Presentation

70 year old WM with 3.0 cm enhancing renal mass. PMH significant for Htn, CAD, DM

#### What is the Best Treatment Option?

**SRM: Active Surveillance**

Surena F. Matin, MD

**SRM: Intervention**

Jose A. Karam, MD

8:30      **Role of Lymph Node Dissection in Locally Advanced Renal Cell**  
**Carcinoma Debate**

#### Case Presentation

55 year old WM with cT3b right renal tumor. No evidence of  
metastatic disease.

**Lymph Node Dissection: Pro**

Christopher G. Wood, MD

**Lymph Node Dissection: Con**

Brian F. Chapin, MD

9:00      **Timing of Cytoreductive Surgery in Metastatic Renal Cell Carcinoma Debate**

### Case Presentation

65 year old WF presents with locally advanced renal primary tumor and pulmonary mets. PS 1. No comorbid conditions.

#### **Upfront Cytoreductive Nephrectomy**

Nizar M. Tannir, MD

#### **Delayed Cytoreductive Nephrectomy**

Eric Jonasch, MD

9:30      **What is the Most Appropriate Front Line Therapy for Metastatic Renal Cell Carcinoma Debate**

### Case Presentation

53 year old WM s/p cytoreductive nephrectomy for a T3aN0M1 ccRCC. PS 0. Labs WNL except Hb 10.3. Bilateral pulmonary metastases.

#### **First Line Therapy: TKI**

Martha P. Mims, MD, PhD

#### **First Line therapy: Immunotherapy**

Nizar M. Tannir, MD

10:00      **Questions and Discussion**

10:10      Break

10:30      **Case Presentations**

*Moderator: Christopher G. Wood, MD*

Panelists: Michael Blute, Sr., MD; Brian F. Chapin, MD; Eric Jonasch, MD; Jose A. Karam, MD; Surena F. Matin, MD; Martha P. Mims, MD, PhD; Wade J. Sexton, MD; Nizar M. Tannir, MD

Noon      Lunch (provided)

## SESSION IV: PROSTATE CANCER

### **Radical Prostatectomy**

*Moderator: John W. Davis, MD*

1:00 p.m.      **How To Improve Urinary and Sexual Function Outcomes**

Surena F. Matin, MD

1:15      **Discussion/Critique**

John F. Ward, MD; Louis L. Pisters, MD; Curtis A. Pettaway, MD

1:25      **How and When to Extend the Pelvic Lymph Node Dissection?**

Brian F. Chapin, MD

1:40      **Discussion/Critique**  
Steven E. Canfield, MD

**Health Services Debate: Robot-Assisted Radical Prostatectomy is a Good Investment**

1:45      **Pro**  
Jay B. Shah, MD

1:55      **Con**  
Karen Hoffman, MD

**Radiation Oncology Updates**

*Moderator: Deborah A. Kuban, MD*

**Technique Debate: Best Radiation Therapy for Localized Prostate Cancer**

2:10      **Proton**  
Seungtaek Choi, MD

2:20      **IMRT**  
Usama Mahmood, MD

2:30      **Brachytherapy**  
Steven J. Frank, MD

2:40      **Discussion/Critique**  
Ana Aparicio, MD; William J. Graber, MD; John N. Papadopoulos, MD

3:00      Break

**Endocrinology and Systemic Therapy Updates**

*Moderator: Christopher J. Logothetis, MD*

3:15      **Testosterone Replacement After Radical Prostatectomy**  
Mohit Khera, MD

3:30      **Zoledronic Acide vs. Denosumab for Metastatic Prostate Cancer**  
Emily Wang, PharmD

3:45      **The Future is Now: Systemic Agents Will Help the Urologist Cure the Uncurable**  
John W. Davis, MD; Christopher J. Logothetis, MD

4:00      **Discussion/Critique**  
Mohit Khera, MD; Emily Wang, PharmD; John W. Davis, MD; Christopher J. Logothetis, MD

## Case Presentations

*Moderators: John W. Davis, MD and Ana Aparicio, MD*

Panelists: Brian F. Chapin, MD; Steven J. Frank, MD; Deborah A. Kuban, MD;  
Christopher J. Logothetis, MD; John F. Ward, MD

4:20      **Topics:**

Sequencing and Combining Novel Systemic Agents

Predicting Failure After Local Therapy. Will Novel Risk Classifiers  
Help Us?

Imaging Challenges

5:00      Adjourn

## MD Anderson Faculty

### **Ana Aparicio, MD**

Assistant Professor  
Genitourinary Medical Oncology

### **Brian F. Chapin, MD**

Assistant Professor  
Urology

### **Seungtaek Choi, MD**

Assistant Professor  
Radiation Oncology

### **John W. Davis, MD**

Associate Professor  
Urology

### **Colin P. Dinney, MD**

Chairman & Professor  
Urology

### **Steven J. Frank, MD**

Associate Professor  
Radiation Oncology

### **Jianjun Gao, MD, PhD**

Assistant Professor  
Genitourinary Medical Oncology

### **William J. Graber, MD**

Associate Professor  
Urology

### **H. Barton Grossman, MD**

Clinical Professor  
Urology

### **Karen Hoffman, MD**

Assistant Professor  
Radiation Oncology

### **Eric Jonasch, MD**

Associate Professor  
Genitourinary Medical Oncology

### **Ashish Kamat, MD**

Associate Professor  
Urology

### **Jose A. Karam, MD**

Assistant Professor  
Urology

### **Deborah A. Kuban, MD**

Professor  
Radiation Oncology

### **Christopher J. Logothetis, MD**

Chairman & Professor  
Genitourinary Medical Oncology

### **Usama Mahmood, MD**

Assistant Professor  
Radiation Oncology

**Surena F. Matin, MD**

Associate Professor  
Urology

**Neema Navai, MD**

Assistant Professor  
Urology

**Yago Nieto, MD**

Professor  
Stem Cell Transplantation

**Lance C. Pagliaro, MD**

Professor  
Genitourinary Medical Oncology

**John N. Papadopoulos, MD**

Assistant Professor  
Urology

**Curtis A. Pettaway, MD**

Professor  
Urology

**Louis L. Pisters, MD**

Professor  
Urology

**Jay B. Shah, MD**

Assistant Professor  
Urology

**Arlene Siefker-Radtke, MD**

Associate Professor  
Genitourinary Medical Oncology

**Nizar M. Tannir, MD**

Associate Professor & Vice Chairman  
Genitourinary Medical Oncology

**Shi-Ming Tu, MD**

Professor  
Genitourinary Medical Oncology

**Emily Wang, PharmD**

Clinical Pharmacy Specialist  
Pharmacy

**Jennifer Wang, MD**

Assistant Professor  
Genitourinary Medical Oncology

**John F. Ward, MD**

Associate Professor  
Urology

**O. Lenaine Westney, MD**

Associate Professor  
Urology

**Christopher G. Wood, MD**

Professor & Vice Chairman  
Urology

## Guest Faculty

**Andrew C. von Eschenbach**

Lecture

**Michael Blute, Sr., MD**

Chief of Urology, Massachusetts  
General Hospital  
Professor of Urology, Harvard  
Medical School  
Boston, Massachusetts

**Distinguished Alumni****Wade J. Sexton, MD**

Associate Professor University  
of South Florida  
Department of Genitourinary Oncology  
Director, Urologic Oncology  
Fellowship Program  
Moffitt Cancer Center  
Tampa, Florida

**Steven E. Canfield, MD**

Associate Professor  
Division of Urology/Department of Surgery  
UT Health Science Center  
Houston, Texas

**Mohit Khara, MD**

Assistant Professor  
Scott Department of Urology/Baylor Clinic  
Baylor College of Medicine  
Houston, Texas

**Martha P. Mims, MD, PhD**

Associate Professor  
Department of Hematology & Oncology  
Baylor College of Medicine  
Houston, Texas

# Registration Information

## Urologic Oncology: Advances in Clinical Practice

On-site registration opens at 7:00 a.m. on **Friday, November 8, 2013**. The conference will begin at 7:50 am on **Friday, November 8, 2013** and adjourn on Saturday, November 9, 2013 at 5:00 p.m. Advance registration is encouraged as space and materials are limited. Please see the registration form for applicable fees.

The full conference registration fee includes the tuition, syllabus, breakfasts, breaks, lunches, and reception.

**The deadline for advance registration is Friday, October 18, 2013.**

### **There are three ways to register:**

- Mail to: CME/Conference Management – Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439
- Fax to: 713-794-1724
- On-line at [www.mdanderson.org/conferences](http://www.mdanderson.org/conferences)

### **We accept the following forms of payment:**

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

When registering online a receipt/confirmation letter will be automatically e-mailed to the e-mail address you list on the registration form. If you register by fax or mail, a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee.

## Refund/Cancellation Policy

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before October 18, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

## Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

## Accommodations

- A block of rooms has been reserved for conference attendees at the **Houston Marriott at the Texas Medical Center**, 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested. To make reservations, please call Marriott Reservations at 800-228-9290 and identify yourself as part of the MD Anderson Urologic Oncology Conference
- The special meeting rate is \$114.00 single or double occupancy. Please add 17% Texas State and local taxes. Reservations and deposits received after October 17, 2013 will be confirmed if space is available and at current hotel published guest room rates.

## Ground Transportation

*(prices are subject to change and variable depending on location of conference)*

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost for \$50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott at the Texas Medical Center for \$27 one-way and \$54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at [www.supershuttle.com](http://www.supershuttle.com).
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott at the Texas Medical Center for \$24 one-way and \$48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at [www.supershuttle.com](http://www.supershuttle.com).

---

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

# CONFERENCE REGISTRATION - PS100595/111409

## 8th Urologic Oncology: Advances in Clinical Practice — November 8-9, 2013

|                                                                                                                                   |            |                             |      |                                               |       |                                                          |          |
|-----------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------|------|-----------------------------------------------|-------|----------------------------------------------------------|----------|
| Last Name                                                                                                                         |            | First                       |      | MI                                            |       | Highest Degree                                           |          |
| Department (include box no.)                                                                                                      |            |                             |      | Specialty                                     |       |                                                          |          |
| Institution                                                                                                                       |            |                             |      | Physician                                     |       | <input type="checkbox"/> Yes <input type="checkbox"/> No |          |
| Street                                                                                                                            |            | City                        |      | State/Foreign Country/Zip or Mail Code        |       |                                                          |          |
| Daytime Phone (with area code)                                                                                                    |            | Cell Phone (with area code) |      | Fax (with area code)                          |       |                                                          |          |
| E-mail Address                                                                                                                    |            | Emergency Contact           |      | Phone (with area code)                        |       |                                                          |          |
| Charge the following: <input type="checkbox"/> VISA <input type="checkbox"/> MasterCard <input type="checkbox"/> American Express |            |                             |      |                                               |       |                                                          |          |
| Credit Card Holder Name (First/Last)                                                                                              |            |                             |      | Credit Card Holder Billing Address & ZIP Code |       |                                                          |          |
| Credit Card Number                                                                                                                |            |                             |      | Expiration Date                               |       |                                                          |          |
| <b>MD Anderson Interdepartmental Transfer (IDT) No.:</b>                                                                          |            |                             |      |                                               |       |                                                          |          |
| Business Unit                                                                                                                     | Department | Fund Group                  | Fund | Fund Type                                     | PC By | Project                                                  | Activity |
| Authorized Signature REQUIRED for credit card or IDT                                                                              |            |                             |      | MD Anderson Employee ID No. (REQUIRED)        |       |                                                          |          |
| IDT Approver Name (First/Last) please print                                                                                       |            |                             |      | IDT Approver E-mail                           |       |                                                          |          |

**THIS IS NOT A SELF-MAILER - Address to:**  
**8th Urologic Oncology: Advances in Clinical Practice**  
**November 8-9, 2013**

Department of CME/Conference Management  
Unit 1381

The University of Texas MD Anderson Cancer Center  
PO Box 301439, Houston, TX 77230-1439  
or fax to 713-794-1724

Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

### GENERAL CONFERENCE REGISTRATION FEES

#### Physicians

- ☐ Postmarked on or before Oct. 18, 2013 ..... \$250.00  
☐ Postmarked after Oct. 18, 2013 ..... \$300.00

#### Students / Trainees / PAs /

#### Advanced Nurse Practitioners

- ☐ Postmarked on or before Oct. 18, 2013 ..... \$55.00  
☐ Postmarked after Oct. 18, 2013 ..... \$80.00

Department of CME/Conference Management - Unit 1381  
The University of Texas MD Anderson Cancer Center  
#176700/111409/PS100595  
PO Box 301439  
Houston, TX 77230-1439

---

Non-Profit Org.  
U.S. Postage  
PAID  
Permit No. 7052  
Houston, TX